NG004 in Spinal Cord Injury Patients

Recruiting Phase 1 Interventional Study
Acute Spinal Cord Injury (SCI) Spinal Cord Diseases Central Nervous System Diseases Nervous System Diseases Trauma, Nervous System Spinal Cord Injuries (SCI) Wounds and Injuries
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 70
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
21 (estimated)
Sponsor
NovaGo Therapeutics AG · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This is the FIH, multicenter, open-label, sequential, multiple ascending dose trial of NG004 in patients with acute incomplete cervical SCI. The trial will evaluate the safety, tolerability, and PK of 4 dose regimens of NG004, and will evaluate the maximum tolerated dose of NG004.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Acute incomplete cervical SCI (Neurological level of injury C1 ≤ lesion ≤ C8) with confirmed classification of American Spinal Injury Association (ASIA) impairment scale (AIS) C-D at Screening * 4-28 days post-injury * No required mechanical ventilation or patients that not co…
Contacts

Director of Clinical Research

+41433005263

clinical@novagotx.com

CONTACT